OncoLife-MM - FISH (plasma cells enrichment)

OncoLife-MM – FISH (Plasma Cell Enrichment)

OncoLife-MM – FISH (Plasma Cell Enrichment) is an advanced genetic test designed to detect chromosomal abnormalities in Multiple Myeloma (MM). By enriching plasma cells from the bone marrow sample before analysis, the test significantly improves the detection of clinically important genetic alterations, helping with diagnosis, risk assessment, prognosis, and treatment planning. Plasma cell enrichment increases the sensitivity of FISH testing compared to standard analysis.

Test Highlights

• Detects key chromosomal abnormalities associated with Multiple Myeloma.
• Uses Fluorescence In Situ Hybridization (FISH) technology on enriched plasma cells.
• Improves detection of low-frequency abnormal plasma cells.
• Supports diagnosis, prognostic classification, and personalized treatment decisions.
• Recommended for newly diagnosed, relapsed, or suspected Multiple Myeloma cases.

Common Genetic Targets

• del(13q14)
• del(17p) (TP53)
• t(11;14) – IGH/CCND1
• t(4;14) – FGFR3/IGH
• t(14;16) – IGH/MAF
• 1q Gain / 1p Deletion
• Other clinically significant abnormalities based on the testing panel.

Specimen

• Bone Marrow Aspirate (preferred)

Method

• Plasma Cell Enrichment
• Fluorescence In Situ Hybridization (FISH)

Clinical Utility

• Diagnosis of Multiple Myeloma
• Risk stratification
• Prognostic evaluation
• Treatment planning
• Disease monitoring when clinically indicated

Turnaround Time

Approximately 5–10 working days (may vary depending on laboratory workflow).